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Deamidated Lipocalin-2 Induces Endothelial Dysfunction and
Hypertension in Dietary Obese Mice
Erfei Song, MMed; Pengcheng Fan, PhD; Bosheng Huang, BSc; Han-Bing Deng, PhD; Bernard Man Yung Cheung, PhD; Michel Feletou, PhD;
Jean-Paul Vilaine, PhD; Nicole Villeneuve, PhD; Aimin Xu, PhD; Paul M. Vanhoutte, MD; Yu Wang, PhD
Background-—Lipocalin-2 is a proinﬂammatory adipokine upregulated in obese humans and animals. A pathogenic role of lipocalin-
2 in hypertension has been suggested. Mice lacking lipocalin-2 are protected from dietary obesity-induced cardiovascular
dysfunctions. Administration of lipocalin-2 causes abnormal vasodilator responses in mice on a high-fat diet (HFD).
Methods and Results-—Wild-type and lipocalin-2 knockout mice were fed with standard chow or HFD. Immunoassays were
performed for evaluating the circulating and tissue contents of lipocalin-2. The relaxation and contraction of arteries were studied
using a wire myograph. Blood pressure was monitored with implantable radio telemetry. Dietary obesity promoted the
accumulation of lipocalin-2 protein in blood and arteries. Deﬁciency of this adipokine protected mice from dietary obesity-induced
elevation of blood pressure. Mass spectrometry analysis revealed that human and murine lipocalin-2 were modiﬁed by
polyamination. Polyaminated lipocalin-2 was rapidly cleared from the circulation. Adipose tissue was a major site for lipocalin-2
deamidation. The circulating levels and the arterial accumulation of deamidated lipocalin-2 were signiﬁcantly enhanced by
treatment with linoleic acid (18:2n6), which bound to lipocalin-2 with high afﬁnity and prevented its interactions with matrix
metalloproteinase 9 (MMP9). Combined administration of linoleic acid with lipocalin-2 caused vascular inﬂammation and
endothelial dysfunction and raised the blood pressure of mice receiving standard chow. A human lipocalin-2 mutant with cysteine
87 replaced by alanine (C87A) contained less polyamines and exhibited a reduced capacity to form heterodimeric complexes with
MMP9. After treatment, C87A remained in the circulation for a prolonged period of time and evoked endothelial dysfunction in the
absence of linoleic acid.
Conclusions-—Polyamination facilitates the clearance of lipocalin-2, whereas the accumulation of deamidated lipocalin-2 in arteries
causes vascular inﬂammation, endothelial dysfunction, and hypertension. ( J Am Heart Assoc. 2014;3:e000837 doi: 10.1161/
JAHA.114.000837)
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H uman lipocalin-2, also called neutrophil gelatinase-associated lipocalin, is a 25-kDa protein originally
puriﬁed from the exocytosed material of neutrophils and
partly associated with the gelatinase, matrix metalloprotein-
ase 9 (MMP9).1 It belongs to the functionally heterogeneous
family of lipocalin proteins, which bind and carry small mol-
ecules to speciﬁc target cells.2 In obese human subjects and
animals, the circulating concentration of lipocalin-2 is
augmented and positively correlated with body-fat mass,
arterial blood pressure (ABP), insulin resistance index, and
abnormal lipid proﬁles.3 Because lipocalin-2 is produced by
adipose tissue, it is regarded as an adipokine.3–5 In mice,
deﬁciency of this adipokine protects against the develop-
ment of endothelial and cardiometabolic dysfunctions
associated with genetic or dietary obesity.6–8 In mice fed
a high-fat diet (HFD), administration of recombinant lipo-
calin-2 protein promotes endothelial dysfunction and induces
adipose tissue inﬂammation.6,7 An augmented lipocalin-2
level is likely to play a causative role in obesity-related
cardiovascular complications, including hypertension and
heart disease.3,9 Despite this information, the mechanisms
responsible for the elevated circulating level of lipocalin-2
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in obese subjects remain largely unknown. Moreover, it
is not clear whether or not this adipokine exerts
direct effects on the arterial wall leading to endothelial
dysfunction.
Endothelial dysfunction occurs at the early stages of
obesity and promotes the development of cardiometabolic
complications.3,10,11 Obesity impairs endothelium-dependent
vasodilator responses to shear stress, insulin, and other
neurohumoral mediators.12 By contrast, weight loss in
obese human subjects substantially improves endothelial
function.13,14 The endothelium of obese subjects is exposed
directly to elevated lipid levels (including free fatty acids,
triglycerides, and low-density lipoproteins [LDLs]). In partic-
ular, circulating nonesteriﬁed free fatty acids (NEFAs) play a
key pathogenic role in obesity-induced endothelial dysfunc-
tion.15–19 It is not known whether or not lipocalin-2-evoked
endothelial dysfunction is related to NEFA-mediated lipotox-
icity under obese conditions. The present study demon-
strates that lipocalin-2 is polyaminated and rapidly cleared
from the circulation. NEFAs upregulate and activate lipoc-
alin-2 by promoting its deamidation. The deamidated
lipocalin-2 accumulates in arteries, inducing endothelial
dysfunction and causing elevated ABP. These lines of
evidence collectively reveal a novel mechanism underlying
obesity-induced endothelial dysfunction and hypertension,
which involves lipid-mediated activation of an inﬂammatory
adipokine, lipocalin-2.
Materials and Methods
Experimental Design
The present study investigated the mechanisms underlying
upregulated lipocalin-2 and the cause-effect relationships with
endothelial dysfunction and hypertension in obese animals.
Data comparisons were performed between mice fed with
standard chow and HFD, or between mice with and without
lipocalin-2 expressions, or among different treatment condi-
tions (vehicle, lipocalin-2 protein, linoleic acid [LA], and
lipocalin-2 plus LA) in age-matched mice under the same type
of diet.
Animal Studies
All the animal experimental procedures were approved by
the Committee on the Use of Live Animals for Teaching and
Research of the University of Hong Kong and carried out
in accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (Publication No. 85-23, revised 1996). Male wild-type
(WT) and lipocalin-2 knockout (Lcn2-KO) mice were main-
tained in a C57BL/6J background.6–8,20 Mice were housed
in a room under controlled temperature (231°C) and 12-
hour light-dark cycle, with free access to water and
standard chow (LabDiet 5053; Purina Mills, Richmond, IN)
or HFD (composed of 21.3% protein, 23.6% fat [primarily
lard; 45% of the caloric intake], 5.8% ﬁber, and 41.2%
carbohydrate; 4.65 kcalg1; D12451; Research Diet, New
Brunswick, NJ). For NEFA administration, mice under
standard chow were fasted (food removal) for 16 hours
and then administered intraperitoneally with a total volume
of 30 lL of solution containing 3 mg of LA, oleic acid (OA),
palmitic acid (PA), docosahexaenoic acid (DHA), or eicosa-
pentaenoic acid (EPA). A lipocalin-2 protein solution (4 lg/
lL in phosphate buffer; 800 lg per mouse) was subse-
quently injected intraperitoneally. MMP9 Inhibitor I (Cat No.
444278; Calbiochem, EMD Chemicals, Inc, San Diego, CA)
was administered by tail vein injection (2 lg per mouse).
Unless speciﬁed otherwise, tissues were collected 6 hours
after treatment.
Production of Lipocalin-2 Protein
Recombinant murine (mlipocalin-2) and human (hlipocalin-2)
lipocalin-2 was expressed, puriﬁed, and endotoxin was
removed as previously described.5–7 Purity of the protein
was conﬁrmed by SDS-PAGE and mass spectrometry (MS)
analysis.
Site-Directed Mutagenesis
The pPRO-His-hLCN2 vector5 was used to generate a
construct pPRO-His-hLCN2-C87A encoding a mutant form of
hlipocalin-2 with the cysteine 87 residue replaced by alanine.
Primers used for mutagenesis were 50-AGGAC
TTTTGTTCCAGGTGCCCAGCCCGGCGAGTTCACG-30 (forward)
and 50-CGTGAACTCGCCGGGCTGGGCACCTGGAACAAAAGTC
CT-30 (reverse). The mutation was veriﬁed by DNA sequencing.
Quantitative Reverse-Transcription Polymerase
Chain Reaction
Quantitation of target genes was performed using SYBR Green
polymerase chain reaction (PCR) Master Mix (Qiagen, Ham-
burg, Germany) and an ABI PRISM 7900 HT Sequence
Detection System (Applied Biosystems, Foster City, CA). The
sequences of the primers used are listed in Table 1. Data
were calculated and are presented as relative expression of
transcripts normalized to GAPDH.
SDS-PAGE, Western Blotting, and ELISA
Protein samples, serum (1.5 lL), or tissue lysates (30 or
50 lg) were incubated with either a Laemmli sample buffer
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or a nonreducing buffer (1% SDS, 5% glycerol, and 10 mmol/
L of Tris-HCl; pH 6.8) at room temperature for 10 minutes
and then separated by SDS-PAGE.21 Protein bands were
visualized by Coomassie Brilliant Blue staining. After trans-
ferring to polyvinylidene diﬂuoride (PVDF) membranes,
Western blotting was performed by incubating with antibod-
ies (Abs) against mlipocalin-2 or hlipocalin-2,5 spermidine,
spermine, and cytochrome P4502C (Abcam, Cambridge, MA),
MMP9 (BD Transduction Laboratories, San Jose, CA) and
beta-actin (Cell Signaling, Beverly, MA), respectively. After
incubation with secondary Ab, the immune complexes were
detected with enhanced chemiluminescence (ECL) reagents
from GE Healthcare (Uppsala, Sweden). Albumin detected
with Ponceau S staining, or immunoglobulin G probed by
Western blotting, was used as a loading control for serum
samples. Beta-actin was probed as a loading control for
tissue samples. Immune complexes were detected with ECL
reagents from GE Healthcare. Total serum lipocalin-2 levels
were measured using an in-house ELISA.5
Immunohistochemistry
Parafﬁn sections (5 lm) were prepared for hematoxylin
staining and immunostaining using in-house Abs against
mlipocalin-2 or hlipocalin-2.5,6 Images were captured and
analyzed under a microscope (Leica Microsystems, Bensheim,
Germany).
Peptide Mass Finger Printing by Matrix-Assisted
Laser Desorption/Ionization Time-of-Flight MS
Analysis
Proteins of interest separated by SDS-PAGE were excised and
digested in gel with trypsin.22 Tryptic peptide mixtures were
then mixed with an equal amount of a-cyano-4-hydroxycin-
namic acid matrix, spotted on the sample plates, and air-dried
for analysis on a 4800 matrix-assisted laser desorption/
ionization dual time-of-ﬂight (MALDI TOF/TOF)TM system
(Applied Biosystems). All ion spectra were recorded in the
positive mode with an acceleration voltage of 20.0 kV. The
spectrometer was externally calibrated by use of Cal Mix 2
standard mixture.
Isometric Force Measurement
Mice were anesthetized with pentobarbital sodium
(30 mgmL1kg1, IP). The thoracic aortae and carotid
arteries were isolated and cut into rings (2 mm length),
which were suspended in a Mulvany-Halpern wire myograph
(Model 610M; Danish Myo Technology A/S, Aarhus, Den-
mark) for recording of isometric force (PowerLab 4SP;
ADInstrruments, Inc., Colorado Springs, CO). The myograph
chambers contained modiﬁed Krebs-Ringer bicarbonate
(KRB) solution (in mmol/L: 118 NaCl, 4.7 KCl, 2.5 CaCl2,
1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and 11.1 D-glucose
Table 1. Sequences of Primers Used for QPCR Analysis
Gene Name
(symbol) Accession ID Sequence Range
Product Size
(bp) Primer Sequences
GAPDH
(GAPD)
GI:126012538 654 to 836 183 Forward 50CAGAACATCATCCCTGCATC30
Reverse 50CTGCTTCACCACCTTCTTGA30
ICAM-1
(Icam1)
GI:30172560 149 to 341 213 Forward 50GTGATGCTCAGGTATCCATCCA30
Reverse 50CACAGTTCTCAAAGCACAGCG30
E-selectin
(Sele)
GI:118130193 141 to 268 128 Forward 50ATGCCTCGCGCTTTCTCTC30
Reverse 50GTAGTCCCGCTGACAGTATGC30
P-selectin
(Selp)
GI:327412298 1345 to 1445 101 Forward 50TGAACTGAAGGGATCAAGAAGACT30
Reverse 50GCCGAGGGACATCATCACAT30
MCP-1
(Ccl2)
GI:141803162 111 to 250 140 Forward 50GCCTGCTGTTCACAGTTGC30
Reverse 50GGTGATCCTCTTGTAGCTCTCC30
TNFa
(Tnf)
GI:518831586 440 to 646 207 Forward 50TGGTGCCTGGTCTGATGATG30
Reverse 50GTGGTAACCGCTCAGGTGTTG30
NGALR
(Lrp2)
GI:124487371 3101 to 3208 127 Forward 50 CCACCCATCCCAACGGCGAC30
Reverse 50 CGGGCTGGGTCTCCCTCACA30
24p3R
(Slc22a)
GI:270341383 752 to 918 186 Forward 50 CGGCCAGGTTTGGCCGTCG30
Reverse 50 GGGTTGGGTCGCACAGCTCC30
Lipocalin-2
(Lcn-2)
GI:34328048 216 to 383 168 Forward 50 GGTTTGGTGGCAGGCTATTA30
Reverse 50 CAGAGTGGCTTTCCCCATAA30
GAPDH indicates glyceraldehyde 3-phosphate dehydrogenase; ICAM-1, intercellular adhesion molecule-1; MCP-1, monocyte chemotactic protein-1; NGALR, neutrophil gelatinase-
associated lipocalin receptor; QPCR, quantitative reverse-transcription polymerase chain reaction; TNF-a, tumor necrosis factor alpha.
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[control solution]). After equilibration, the aortae were
contracted with phenylephrine (105 mol/L) before being
exposed to increasing concentrations of acetylcholine (ACh;
1010 to 104.5 mol/L; Sigma-Aldrich, St. Louis, MO).
Decreases in tension are expressed as the percentage of
the contraction to phenylephrine. In addition, the aortae
were contracted with thromboxane-prostanoid receptor
agonist U46619 (1 to 39108 mol/L; Biomol, Plymouth
Meeting, PA) before being exposed to increasing concen-
trations of insulin (1010 to 39106 mol/L; Actrapid HM,
Novo Nordisk, Bagsvaerd, Denmark). Decreases in tension
are expressed as the percentage of the contraction to
U46619. Carotid arteries were preincubated with N-nitro-L-
arginine methyl ester (L-NAME; nitric oxide synthase [NOS]
inhibitor; 104 mol/L) for 40 minutes and then exposed to
increasing concentrations of ACh (1010 to 39104 mol/L;
Sigma Aldrich, St. Louis, MO). Increases in tension are
expressed as the percentage of a reference contraction to
KCl (60 mmol/L) obtained at the beginning of the
experiment.
Blood Pressure Measurement
Blood pressure was measured using an implantable telemetry
system (Data Sciences International, St. Paul, MN). In brief,
WT and Lcn2-KO mice were anesthetized with a Hypnorm/
Dormicum mixture (Hypnorm: 0.315 mg/mL of fentanyl and
10 mg/mL of ﬂuanisone [VetaPharma Ltd, Leeds, UK];
Dormicum: 5 mg/mL of midazolam [Roche A/S, Hvidovre,
Denmark]). Telemetry catheters (HD-X11 or PA-C10; Data
Sciences International, St. Paul, MN) were inserted into the
left common carotid artery with the transmitter implanted
subcutaneously. Mice were housed individually in a temper-
ature- and humidity-controlled facility and maintained under a
12-hour dark (lights off 7:00 PM) and 12-hour light (lights on
7:00 AM) cycle. Blood pressure was recorded for at least four
12/12 light-dark cycles using the Dataquest A.R.T system
(Data Sciences International).
Isothermal Titration Calorimetry Analysis
Thermodynamic parameters of fatty acids (FAs) binding to
lipocalin-2 were determined by isothermal titration micro-
calorimetry utilizing an iTC200 microcalorimeter (MicroCal,
Northampton, MA). FAs (300 lmol/L) were prepared in a
buffer containing 20 mmol/L of TrisHCl (pH 8.0) and 50%
glycerol. FAs were titrated (2.0 lL/injection) into a solution
of protein (20 lmol/L in 20 mmol/L of TrisHCl [pH 8.0]/
50% glycerol) at 25°C, and the amount of heat released or
absorbed was measured. Three sets of controls were
performed for each experiment: buffer injected into buffer;
FAs injected into buffer; and buffer injected into protein. Data
were analyzed using the MicroCal Origin v7.0383 software
supplied with the iTC200 microcalorimeter.
Molecular Docking
The program AutoDock Version 4.0 (Scripps Research Insti-
tute, La Jolla, CA) was used for docking ﬂexible ligands into
hlipocalin-2 binding sites. For each ligand, the number of
genetic algorithm runs was 80, the population size was set to
150, and the maximal number of energy evaluations was
2 500 000 per run. The grid box was centered on the
coordinates 51.294, 100.067, and 35.44 with a spacing of
0.581. All other parameters were kept at their default settings.
The protein structure was 3CMP from the Protein Data Bank.
Bacterial siderophore was used as a reference. Chemical
structures of all ligands were downloaded from Pubchem and
modiﬁed by Accelrys Discovery Studio Visualizer 2.5 software.
Statistical Analysis
All Western blotting and histological analysis were repeated at
least 3 times using different sets of experimental animals. For
comparing endothelial functions, statistical calculations were
performed by one-way ANOVAs followed by Tukey’s multiple
comparisons using Prism version 5 (GraphPad Software Inc.,
San Diego, CA). Statistical calculations for blood pressure
differences between WT and age-matched Lcn2-KO mice were
compared by Student t test. Mann-Whitney’s nonparametric
U test was used for evaluating the differences of blood
pressure in mice subjected to acute treatment with or without
recombinant lipocalin-2 and/or LA, lipocalin-2 levels in mice
under standard chow and HFD, and interactions between
lipocalin-2 and NEFAs. All values are presented as mean-
sSEM. For all statistical comparisons, a P value <0.05 was
accepted to indicate signiﬁcant differences.
Results
Lipocalin-2 Protein Is Accumulated in Aortae of
Obese Mice With Elevated Blood Pressure
Circulating lipocalin-2 level is signiﬁcantly elevated in obese
humans and genetically obese animals.5 The present study
demonstrated that obesity induced by long-term consumption
of HFD in WT mice also caused a signiﬁcant elevation of
circulating lipocalin-2, as revealed by both ELISA and Western
blotting analysis (Figure 1A and 1B). In line with the
deterioration of endothelial vasodilator functions,7 lipocalin-
2 protein progressively accumulated in aortic tissues of WT
mice receiving a HFD (Figure 1C). Positive immunostaining
signals of lipocalin-2 were mainly detected in the intima layer
of the aortic wall (Figure 1D). The mRNA of lipocalin-2 was
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undetectable in aortae of obese WT mice, suggesting that
accumulation of this protein was not the result of local gene
expression. The aortic expression of lipocalin-2 receptors
and serum adiponectin levels were not signiﬁcantly different
between WT and Lcn2-KO mice (Figure S1, upper panel).
Radiotelemetry measurement demonstrated that obese
mice deﬁcient with lipocalin-2 exhibited signiﬁcantly lower
mean arterial pressure (MAP), systolic blood pressure (SBP),
and diastolic blood pressure (DBP) than those of obese WT
mice (Table 2). Moreover, after 8 weeks of HFD, the diurnal
rhythms in blood pressure were blunted in WT mice, but
maintained in Lcn2-KO mice. HFD-induced arterial inﬂamma-
tion was signiﬁcantly attenuated by lipocalin-2 deﬁciency
(Figure S1, lower panel). These ﬁndings suggest that
accumulation of lipocalin-2 in arteries of obese mice contrib-
utes to the development of dietary obesity-induced endothe-
lial dysfunction and hypertension.
Endogenous Lipocalin-2 Is Polyaminated
Western blotting analysis revealed that in the serum of WT
mice fed with standard chow, a single slow-migrating band of
lipocalin-2 was detected in SDS-PAGE gel. In serum of WT
mice fed with HFD, lipocalin-2 was not only upregulated,
but also the protein migrated as a high- (HMW) and a low-
molecular-weight (LWM) species (Figure 2A, left panel).
Lipocalin-2 mainly accumulated as the LMW species in both
blood and aortae of WT mice after prolonged HFD (Figure 1B
and 1C). In adipose tissues of WT mice, both HMW and LWM
species of lipocalin-2 were detectable, whereas only HMW
species was present in liver samples (Figure 2A, right panel).
In Lcn2-KO mice, after intraperitoneal administration of
recombinant mlipocalin-2 (left panel) or hlipocalin-2 (right
panel), a species equivalent to the injected protein was
present in the serum of animals fed either standard chow or
HFD (Figure 2B). In addition, an immunoreactive protein band
with a lower molecular weight was revealed by Western
blotting in serum derived from HFD-fed Lcn2-KO mice.
The differences between HMW and LMW species of
lipocalin-2 were further investigated. After incubation in KRB
buffer for different periods of time, recombinant hlipocalin-2
remained as one species, as revealed by Coomassie Brilliant
Blue staining of the SDS-PAGE gels (Figure 2C, left panel).
After prolonged incubation with adipose tissue derived from
obese Lcn2-KO mice, which contained no endogenous
lipocalin-2, a LMW protein species appeared (Figure 2C, left
panel). In-gel digestion and MS analysis conﬁrmed the
identities of both HMW and LMW protein bands as hlipoc-
alin-2. Moreover, the peptides corresponding to NH2- and
COOH-terminus of hlipocalin-2 were present in both spectra
(Figure S2), suggesting that the LMW species was not a
cleaved fragment of the HMW species. On the other hand,
Figure 1. Accumulation of lipocalin-2 in arteries of obese mice.
A, Serum concentrations of lipocalin-2 in WT mice given high fat
diet (HFD) for different periods were measured by an in-house
ELISA. *P<0.05 versus standard chow group; n=3 to 5 in all
groups. B, Western blotting analysis of sera collected from WT
mice after different periods of HFD. Recombinant mlipocalin-2
was used as the standard and serum from Lcn2-KO mice was
included for comparison. C, Aortic accumulation of lipocalin-2 was
monitored by Western blotting. The same amount (50 lg) of
proteins was loaded for each sample. b-actin was probed as the
loading control. D, Immunohistochemistry was performed in
aortae sections collected from WT mice under standard chow or
HFD. Magniﬁcation, 9400. ELISA indicates enzyme-linked immu-
nosorbent assay; Lcn2-KO, lipocalin-2 knockout; WT, wild type.
Table 2. Blood Pressures in Conscious Mice (12 Weeks Old, High-Fat Diet) Implanted With Telemetry Devices
Mean Arterial Pressure (mm Hg) Systolic Blood Pressure (mm Hg) Diastolic Blood Pressure (mm Hg)
WT Lcn2-KO WT Lcn2-KO WT Lcn2-KO
24-hour average 133.115.5 115.516.6# 142.816.3 122.417.1# 123.415.6 108.716.2#
Light cycle average (7:00 AM to 7:00 PM) 129.515.5 107.313.8# 138.316.2 113.714.2# 120.615.3 100.913.4#
Dark cycle average (7:00 PM to 7:00 AM) 136.814.7 123.714.5* 147.315.1 131.114.9* 126.215.3 116.414.3*
Lcn2-KO indicates lipocalin-2 knockout; WT, wild type.
*P<0.05 and #P<0.01 versus the corresponding WT mice controls; n=4 in both groups.
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a cluster of masses differing by 57, 87, 144, and 201 Da
(1938.8276 versus 1995.8311, 2101.8926 versus
2188.9211, 2101.8926 versus 2145.9375, and 2101.8926
versus 2302.9563) was observed in the spectrum of the
HMW species, but was absent in that of LMW hlipocalin-2
(Figure 2C, right panel), suggesting that this protein is
modiﬁed by polyamination and that the polyamine groups
are removed in the presence of adipose tissue from obese
mice. The cluster of the modiﬁed peaks also existed in the
HMW species of recombinant mlipocalin-2 (Figure S3).
Western blotting conﬁrmed that mlipocalin-2 and hlipocalin-
2 were both cross-reactive to Abs recognizing the 2 widely
Figure 2. Lipocalin-2 is modiﬁed by polyamination. A, Western blotting was performed for detection of
lipoclain-2 in serum (1.5 lL/lane) derived from WT mice fed with standard chow (SC) or high fat diet HFD
(left panel), and in tissue lysates (epididymal adipose fat and liver, 50 lg/lane) derived from WT mice fed
with HF (right panel). B, Lipocalin-2 knockout (Lcn2-KO) mice fed with SC or HF were injected
intraperitoneally with murine lipocalin-2 (mlipocalin-2, left panel) or human lipocalin-2 (hlipocalin-2, right
panel). Six hours after treatment, sera were collected and subjected to Western blotting. Puriﬁed
recombinant protein was included in each gel for comparison. C, Recombinant hlipocalin-2 protein was
incubated in KRB solution with or without the adipose tissues derived from obese Lcn2-KO mice for
different time points. Protein in solution was then analyzed by SDS-PAGE and Coomassie Brilliant Blue
(CBB) staining (left panel). Protein bands were cut for in-gel trypsin digestion and mass spectrometric
analysis by MALDI-TOF.22 Mass ﬁnger-printing spectra containing the polyaminated peptide peaks are
shown (right panel). D, Puriﬁed recombinant mlipocalin-2 and hlipocalin-2 were separated by SDS-PAGE and
visualized by CBB staining or Western blotting using antibodies recognizing spermidine or spermine.
E, Coimmunoprecipitation was performed to precipitate lipocalin-2 protein from adipose tissue lysates
(500 lg, left panel) and concentrated urine sample (right panel) from human subjects. Immune complexes
were separated by SDS-PAGE and Western blotting was performed using antibodies recognizing hlipocalin-2
or spermidine. HMW indicates high molecular weight; KRB, Krebs-Ringer bicarbonate; LMW, low molecular
weight; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-ﬂight; WT, wild type.
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distributed aliphatic polyamines,23 spermidine and spermine
(Figure 2D). Immunoprecipitation was performed using adi-
pose tissues and urine collected from human subjects.
Western blotting conﬁrmed that the precipitated hlipocalin-2
was polyaminated in both adipose tissue and urine (Fig-
ure 2E). Because mlipocalin-2 and hlipocalin-2 showed
similar properties, unless speciﬁed otherwise, subsequent
studies used recombinant hlipocalin-2 and were performed in
Lcn2-KO mice to avoid the inﬂuence from endogenous
lipocalin-2.
LA Promotes Lipocalin-2 Deamidation
The above data demonstrate that human and murine lipocalin-
2 are polyaminated. Deamidation (removal of polyamine
groups) of lipocalin-2 is facilitated under conditions such as
diet-induced obesity. HFD increases circulating levels of
NEFAs.24,25 Therefore, the effects of individual NEFAs on
circulating hlipocalin-2 were evaluated. Recombinant hlipoc-
alin-2 protein was given intraperitoneally to Lcn2-KO mice
maintained on standard chow, with or without combined
administration of saturated PA, monounsaturated OA, long-
chain polyunsaturated LA, DHA, or EPA. Two hours after the
injection, two strongly immunoreactive protein bands were
detected by Western blotting in the serum collected from
mice treated with hlipocalin-2 plus LA (Figure 3A, upper
panel). ELISA results revealed that combined administration of
hlipocalin-2 and LA signiﬁcantly elevated the circulating
amount of hlipocalin-2 more than 8-fold, when compared to
animals injected with hlipocalin-2 alone (Figure 3A, bottom
panel). Protein of hlipocalin-2 remained low or undetectable in
sera samples collected from those with combined treatments
of other NEFAs. Time-course evaluation by Western blotting
demonstrated that combined LA administration prevented the
clearance of circulating hlipocalin-2 from Lcn2-KO mice
receiving standard chow. Without LA, hlipocalin-2 was unde-
tectable in serum 4 hours after injection. By contrast,
deamidated hlipocalin-2 could still be readily detected in
serum of mice 12 hours after injection of the protein in
combination with LA (Figure 3B).
Next, in vitro incubation of recombinant protein with sera
or tissues derived from Lcn2-KO mice was performed to test
the effects of LA on hlipocalin-2 deamidation. After coincu-
bation with serum, adipose tissue, liver, or kidney derived
from mice fed standard chow, hlipocalin-2 remained as one
species (Figure 3C). A small amount of LMW species of
hlipocalin-2 appeared when LA was present during coincuba-
tion with serum, adipose tissue, and kidney (Figure 3D). By
contrast, without the addition of LA, a large amount of
deamidated hlipocalin-2 was readily formed after incubation
with adipose tissue or kidney derived from Lcn2-KO mice fed
HFD (Figure 3E). Moreover, coincubation with adipose tissue
or kidney collected from Lcn2-KO mice treated with LA
(intraperitoneal injection) promoted hlipocalin-2 deamidation
(Figure 3F). Thus, adipose tissue represents a major site for
deamidation of hlipocalin-2, which can be facilitated by LA or
dietary obesity.
Reduced Interactions Between Deamidated
Lipocalin-2 and MMP9
Isothermal titration calorimetry was applied to investigate
the molecular interactions between lipocalin-2 and NEFAs.
Thermodynamic parameters were measured to indicate
binding strength and interaction force. The dissociation
constants for the lipocalin-2/NEFA complex at pH 7.4 were
0.487, 2744.343, and 1467.45 lmol/L for LA, PA, and OA,
respectively (Figure 4), suggesting that lipocalin-2 could bind
to LA with a stronger afﬁnity than the other two NEFAs. In
fact, molecular docking simulation suggested that among all
tested FAs, lipocalin-2 possessed the highest binding afﬁnity
with LA (Table 3).
MMP9 and lipocalin-2 form heterodimers.26 The cysteine
87 (C87) residue of human lipocalin-2 may play a role in
covalent binding with MMP9.27 SDS-PAGE and Western
blotting revealed that the hlipocalin-2 mutant, C87A (C87
replaced by alanine), contained a signiﬁcantly lesser amount
of polyamines, when compared to that of WT hlipocalin-2
(Figure 5A, left panel). Analysis with nonreducing SDS-PAGE
demonstrated that the ratio of homodimer/monomer was
below 1:10 for WT hlipocalin-2, but over 10:1 for C87A
(Figure 5A, right panel). In addition, C87A formed even higher
molecular weight species that contained no polyamine
signals. In Lcn2-KO mice, interaction between C87A and
MMP9 was signiﬁcantly decreased, compared to that of WT
hlipocalin-2 (Figure 5B, left panel). Combined treatment with
LA also abolished interactions between MMP9 and hlipocalin-
2 (Figure 5B, right panel). In serum of obese humans,
interactions between MMP9 and lipocalin-2 were reduced
(Figure S4).
Binding with LA may contribute to deamidation of hlipoc-
alin-2 and subsequent dissociation from MMP9, or vice versa.
The latter possibility was tested in Lcn2-KO mice treated with
MMP9 Inhibitor I (MMP9i; 2 lg/mouse) before administration
of hlipocalin-2. Although the total amount of hlipocalin-2 in
the circulation was signiﬁcantly augmented, MMP9i did not
facilitate deamidation of this protein as efﬁciently as that of
LA (Figure 5C, upper panel). In Lcn2-KO mice, the amount of
C87A in the circulation was still detectable by Western
blotting at 6 hours after treatment. In SDS-PAGE, C87A
migrated to the same position as the deamidated lipocalin-2
species in samples from mice subjected to combined
treatment with LA and hlipocalin-2 (Figure 5C, upper panel).
Analysis of aortae derived from these mice revealed a large
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Figure 3. Deamidation of lipocalin-2. A, Recombinant hlipocalin-2 was injected intraperitoneally into Lcn2-KO mice under standard
chow (SC). Immediately before protein treatment, mice were administered with or without palmitic acid, oleic acid, linoleic acid (LA),
DHA, and EPA, respectively. Sera were collected 2 hours after treatment for measuring circulating lipocalin-2 levels by Western
blotting (upper panel). ELISA results were shown for sera collected at 6 hours after injection (bottom panel). Murine IgG was probed
as a loading control. *P<0.05 versus hlipocalin-2-treated samples; n=12 to 15 in all groups. B, Lcn2-KO mice under SC were treated
with hlipocalin-2, combined with or without LA as in (A). At different time points after injection, serum was collected from tail vein and
subjected to Western blotting analysis of circulating hlipocalin-2. Albumin, as shown in membrane stained with Ponceau S, was used
as the loading control. C, Recombinant hlipocalin-2 (5 lg) was incubated in 100 lL of KRB solution containing serum (5%) or 100 mg
of tissues (epididymal fat, liver, or kidney) collected from Lcn2-KO mice (8 weeks of age) under SC. The solution was collected at 1, 2,
and 4 hours of incubation and subjected to Western blotting analysis using antibody recognizing hlipocalin-2. D, Recombinant
hlipocalin-2 (5 lg) was incubated with serum or tissues as in (C) in the presence of LA (1 mg/well) and analyzed by Western blotting.
E, Recombinant hlipocalin-2 (5 lg) was incubated in KRB solution containing serum, adipose tissue, liver, or kidney collected from
Lcn2-KO mice (8 weeks of age) under HFD. Western blotting was performed as in (C and D). F, Recombinant hlipocalin-2 (5 lg) was
incubated with serum or tissues collected from Lcn2-KO mice (under SC, treated with LA [3 lg/mouse] for 1 hour) as in (C) and
analyzed by Western blotting. DHA indicates docosahexaenoic acid; ELISA, enzyme-linked immunosorbent assay; EPA,
eicosapentaenoic acid; HF, high fat diet; IgG, immunoglobulin G; KRB, Krebs-Ringer bicarbonate; Lcn2-KO, lipocalin-2 knockout.
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amount of accumulated C87A, similar to those treated with
WT hlipocalin-2 plus LA (Figure 5C, lower panel). On the other
hand, hlipocalin-2 was barely detectable in aortae of mice
given the protein alone. Aortae of mice treated with MMP9i
contained 2 species of hlipocalin-2, both of which migrated at
a higher molecular weight position than C87A (Figure 5C,
lower panel). Time-course studies revealed that after treat-
ment, C87A remained stable in the circulation of Lcn2-KO
mice throughout the 24-hour observation period (Figure 5D,
upper panel). C87A protein mainly accumulated in adipose
tissue and aortae (Figure 5D, lower panel).
The above results suggest that polyaminated lipocalin-2
binds to MMP9 and is rapidly cleared from the circulation,
whereas deamidated lipocalin-2 accumulates in the circula-
tion and tissues, such as the aortae.
Deamidated Lipocalin-2 Causes Endothelial
Dysfunction and Hypertension
Next, arterial function in mice treated with polyaminated (WT
hlipocalin-2) and deamidated (C87A) lipocalin-2 was evalu-
ated. After in vivo administration to Lcn2-KO mice with
recombinant hlipocalin-2 alone, only a small amount of
polyaminated lipocalin-2 was detected in aortae (Figure 5C),
and no signiﬁcant effects were observed on expression of
endothelial NOS (eNOS), cyclooxygenase-2 (COX-2), and
cytochrome P450 2C (Cyp2C) (Figure 6A). Combined treat-
ment with hlipocalin-2 plus LA or administration of C87A
triggered accumulation of a large amount of deamidated
lipocalin-2 in aortae of Lcn2-KO mice (Figure 5C), accompa-
Table 3. Calculated Binding Afﬁnities Between Lipocalin-2 and Various Fatty Acids by Molecular Docking
Ligand DG (kcal/mol) Kd (nmol/L)
Arachidonic acid 6.1 35.8
20-Hydroxyeicosatetraenoic acid 6.2 30.2
12-Hydroxyeicosatetraenoic acid 4.0 1026.7
5-Hydroxyeicosatetraenoic acid 4.4 620.4
Prostaglandin F2 6.2 30.2
Prostaglandin H2 5.9 50.1
Prostaglandin D2 4.6 443.4
Linoleic acid 7.3 4.7
Oleic acid 4.2 867.9
Palmitic acid 3.2 4649.3
Arachidic acid 3.1 5499.1
Stearic acid 3.2 4649.3
Enterochelin* 8.7 0.5
*A ligand of lipocalin-2 (http://www.rcsb.org/pdb/explore.do?structureId=3CMP) was included as the reference control.
Figure 4. Lipocalin-2 binds with
linoleic acid with high afﬁnity. Ther-
modynamic parameters of noneste-
riﬁed free fatty acids (NEFAs)
binding to hlipocalin-2 were deter-
mined by isothermal titration mic-
rocalorimetry. Changes in Gibbs
free energy (DG) and equilibrium
dissociation constant (Kd) are pre-
sented as meansSEM. *P<0.01
versus other conditions; n=5 in all
groups.
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nied by eNOS uncoupling as well as signiﬁcant induction of
COX-2 and Cyp2C (Figure 6A). Quantitative PCR (QPCR)
analysis revealed that C87A elicited similar proinﬂammatory
effects to combined administration of lipocalin-2 and LA.
Expressions of inﬂammatory genes, including E-selectin, P-
selectin, tumor necrosis factor alpha (TNF-a), and intercellular
adhesion molecule-1 (ICAM-1), were augmented signiﬁcantly
by both treatments (Figure 6B).
WT hlipocalin-2, when given alone, had no signiﬁcant effect
on vascular tone responsiveness. However, lipocalin-2 plus LA
treatment attenuated ACh- and insulin-induced relaxations
(because of activation of eNOS and release of nitric oxide
[NO]7,28) in aortae and enhanced ACh-evoked contractions
(because of release of endothelium-derived vasoconstrictor
prostanoids29) in the carotid artery, whereas administration of
the protein or LA alone had no signiﬁcant effects (Figure 6C).
Relaxation to sodium nitroprusside (1010 to 105 mol/L), an
endothelium-independent dilator, was not different between
groups (Figure S5). Treatment of Lcn2-KO mice with C87A
mutant alone reduced relaxations to ACh or insulin in aortae
and augmented contractions to ACh in carotid arteries to a
similar extent as changes observed with combined adminis-
tration of hlipocalin-2 and LA (Figure 6C).
Figure 5. Reduced polyamination of human lipocalin-2 mutant C87A. A, Recombinant hlipocalin-2 and
C87A mutant (3 lg) were separated by reducing (left panel) or nonreducing (right panel) SDS-PAGE and
staining with Coomassie Brilliant Blue (CBB). After transferring to PVDF membrane, Western blotting was
performed to detect spermidine. B, Coimmunoprecipitation was performed using 30 lL of serum from
Lcn2-KO mice treated with vehicle, hlipocalin-2, C87A, or hlipocalin-2 plus linoleic acid (LA). Immune
complexes were separated by SDS-PAGE and subjected to Western blotting using antibodies recognizing
MMP9 or hlipocalin (Lcn2). C, Wild-type hlipocalin-2 or C87A was given to Lcn2-KO mice under standard
chow. Before administration of hlipocalin-2, mice were treated with or without MMP9 Inhibitor I (MMP9i;
2 lg/mouse, tail vein injection) or LA (3 mg/mouse, intraperitoneal injection). Six hours after treatment,
sera and aortae were collected for Western blotting to evaluate hlipocalin-2 levels. Nonspeciﬁc serum IgG
and b-actin was probed as the loading controls, respectively. D, Lcn2-KO mice under standard chow were
treated with C87A, without combined administration of LA. At different time points after injection, serum
was collected from tail vein and subjected to Western blotting analysis of circulating C87A using hlipocalin-
2 antibody (upper panel). At the end of treatment, tissues were also collected for analyzing the accumulated
C87A protein (lower panel). IgG indicates immunoglobulin G; Lcn2-KO, lipocalin-2 knockout; MMP9, matrix
metalloproteinase 9.
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Similar treatment was performed in WT mice fed standard
chow. As shown in Figure 7A, LA promoted accumulation
of endogenous deamidated lipocalin-2 in the blood. After
injection, hlipocalin-2 appeared only transiently in the circu-
lation, whereas combined treatment with LA signiﬁcantly
extended the circulating life of hlipocalin-2, especially that of
its deamidated species. In aortae, treatment with LA
enhanced accumulation of endogenous mlipocalin-2, as well
as that of recombinant hlipocalin-2 (Figure 7B, upper panel).
QPCR analysis further conﬁrmed that increased accumulation
of lipocalin-2 was associated with an augmented expression
of inﬂammatory genes in the aortae (Figure 7B, lower panel).
In line with the amount of deamidated lipocalin-2 accumulat-
ing in the aortic wall, endothelial function was signiﬁcantly
reduced in mice treated with either LA or hlipocalin-2 plus
LA (Figure 7C). Moreover, this combined treatment caused a
signiﬁcant elevation of MAP, SBP, and DBP in WT mice
(Figure 8).
Figure 6. Deamidated lipocalin-2 causes vascular inﬂammation and endothelial dysfunction in Lcn2-KO
mice. A, Lcn2-KO mice (12 weeks old, under standard chow [SC]), were treated with vehicle, hlipocalin-2,
linoleic acid (LA), C87A, or hlipocali-2 plus LA. Six hours after treatment, aortae were collected and analyzed
by Western blotting using speciﬁc antibodies as indicated. b-actin was monitored as the loading control.
B, QPCR was performed to evaluate the inﬂammatory gene expressions in aortae collected from mice
treated as in (A). C, Aortae were collected from mice treated as in (A) to evaluate relaxations to
acetylcholine (ACh) (upper panel) or insulin (middle panel). Contractions to ACh (in the presence of
104 mol/L of L-NAME) were obtained in quiescent carotid arteries (lower panel) of these mice. *P<0.05
versus vehicle control group; n=8 to 10 in all groups. COX-2 indicates cyclooxygenase 2; Cyp2C,
cytochrome P450 2C; eNOS, endothelial nitric oxide synthase; ICAM-1, intercellular adhesion molecule-1;
Lcn2-KO, lipocalin-2 knockout; L-NAME, N-nitro-L-arginine methyl ester; PE, phenylephrine; QPCR,
quantitative reverse-transcription polymerase chain reaction; TNF-a, tumor necrosis factor alpha.
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Treatment with diﬂuoromethylornithine, an irreversible
inhibitor of the polyamine synthase, ornithine decarboxylase,
further increased the amount of deamidated lipocalin-2 in
the circulation as well as pervascular adipose tissues of
WT mice receiving a HFD for 20 weeks (Figure S6).
The 24-hour average of MAP (180.319.1 mm Hg), SBP
Figure 7. Linoleic acid (LA) promotes lipocalin-2 deamidation and accumulation in WT mice. A, WT mice
under standard chow were treated with LA, hlipocalin-2, or hlipocalin-2 plus LA. At different time points
after injection, serum was collected from tail vein and subjected to Western blotting analysis of circulating
murine (upper panel) or human lipocalin-2 (middle and lower panels) using speciﬁc in-house antibodies.5
Albumin stained with Ponceau S was used as the loading control. B, Aortae were collected from WT mice
subjected to different treatments as above. Western blotting was performed for analyzing the amount of
endogenous mlipocalin-2 and the accumulation of exogenous hlipocalin-2 (upper panel). b-actin was probed
as the loading control. QPCR was performed for gene expression comparison, as described in Materials and
Methods (lower panel). C, Aortae were collected from the above treated mice to evaluate relaxations to
acetylcholine (ACh) (left panel). Contractions to ACh (in the presence of 104 mol/L of L-NAME) were
obtained in quiescent carotid arteries (right panel) of these mice. *P<0.05 versus vehicle control group; n=3
to 5 in all groups. ICAM-1 indicates intercellular adhesion molecule-1; L-NAME, N-nitro-L-arginine methyl
ester; PE, phenylephrine; QPCR, quantitative reverse-transcription polymerase chain reaction; TNF-a, tumor
necrosis factor alpha; WT, wild type.
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(185.917.9 mm Hg), and DBP (176.719.0 mm Hg) of
these mice was elevated by 21%, 20%, and 23%, respectively,
when compared to vehicle-treated animals.
Taken in conjunction, the evidence suggests that increased
uptake of NEFAs (in particular, LA), such as during dietary
obesity, promotes accumulation of deamidated lipocalin-2 in
arteries, which subsequently causes endothelial dysfunction,
vascular inﬂammation, and hypertension.
Discussion
Endothelial dysfunction is an early manifestation of obesity
and contributes to progression of overt cardiovascular and
metabolic morbidity.10,30 In obese subjects, elevated circu-
lating NEFA levels (resulting largely from lipase-mediated
hydrolysis of lipoproteins and increased drainage from
hypertrophic adipocytes) and abnormal production of adipo-
kines cause impairment of endothelial vasomotor function,
in particular, blunting endothelium-dependent vasodilata-
tion.17,31,32 In addition, dietary intake of saturated, monoun-
saturated, and polyunsaturated fatty acids has a signiﬁcant
effect on distribution of circulating lipids and vascular
reactivity.33–35 Pharmacological interventions that decrease
circulating lipid levels directly improve endothelial function
and reduce vascular inﬂammation.36 However, the molecular
mechanisms underlying impairment of vascular function by
NEFAs remain largely unclear.
Adipose tissue, especially perivascular adipose tissue, is a
major source of adipokines that exert paracrine, as well as
endocrine, effects on vasomotor activity.37 Among them,
“good” adipokines, such as adiponectin, promote vasodilata-
tion and endothelial function, whereas “bad” adipokines
aggravate obesity-induced endothelial dysfunction and vascu-
lar inﬂammation.3,38 Lipocalin-2 is such a proinﬂammatory
adipokine upregulated in obese human subjects and animals.5
In obese mice, lipocalin-2 treatment induces endothelial
dysfunction by promoting oxidative stress and eNOS uncou-
pling.7 The present study reveals that lipocalin-2 is polyami-
nated and that the proinﬂammatory and endothelial damaging
effects of this adipokine are mediated by its deamidated form.
Adipose tissue represents a major site for lipocalin-2 deam-
idation, a process that can be facilitated by treatment with LA
or HFD. Thus, it is reasonable to conclude that elevated
NEFAs in dietary obesity enhance production and function of
the proinﬂammatory form and deamidated lipocalin-2, which
negatively modulates endothelial function and vascular tone.
The composition of NEFAs, rather than their total amounts,
is relevant for endothelial function. Acute treatment with long-
chain, but not medium-chain, NEFAs attenuates endothelium-
dependent vasodilatation.16 Omega-6 fatty acids, especially
LA, cause endothelial cell dysfunction and potentiate TNF-a-
mediated endothelial injury.39 LA is enriched in LDL choles-
terol esters that promote endothelial activation by enhancing
expression of adhesion molecules and decreasing eNOS
activity.40,41 High intake of LA-rich oils or fats leads to cellular
oxidative stress and inﬂammatory responses.42 The present
results from isothermal titration calorimetry analysis demon-
strate that lipocalin-2 binds to LA with a higher afﬁnity than
those of the saturated PA and monounsaturated OA.
Compared to other members of the lipocalin family, lipoca-
lin-2 displays an unusually large ligand-binding cavity lined
with polar and positively charged amino acid residues.43
Consistent with the present ﬁndings, crystal structure analy-
sis reveals that an FA complex is present in the ligand-binding
pocket of dimeric hlipocalin-2, but not in that of lipocalin-2
Figure 8. Lipocalin-2 treatment in combination
with linoleic acid (LA) promotes the elevation of
blood pressure. Wild-type (WT) mice (6 weeks old,
standard chow) were implanted with the telemetry
transmitter as described in Materials and Methods,
and allowed 2 weeks of recovery from the surgery.
Blood pressure was monitored after injection with
vehicle, hlipocalin-2, linoleic acid (LA), or hlipocalin-
2 in combination with LA. The results show that, at
5 hours after injection, systolic, diastolic, and mean
arterial pressures were signiﬁcantly increased in
mice treated with hlipocalin-2 in combination with
LA. *P<0.05 versus other treatments; n=3 in all
groups.
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monomer.43 By binding to the pocket, LA may alter the
protein structure of lipocalin-2 and its interactions with other
binding partners, such as MMP9, which facilitates deamida-
tion of the adipokine. LA and polyamines may interact with
lipocalin-2 by binding to distinct cavities.44 Deamidated
lipocalin-2 has a strong tendency to form homodimers as
well as HMW multimers, but shows decreased capacity to
form heterodimers with MMP9. On the other hand, polyami-
nated lipocalin-2 binds to MMP9 and exhibits a much shorter
plasma half-life, when compared to deamidated lipocalin-2,
indicating that formation of heterodimer with MMP9 facili-
tates clearance of the adipokine from the circulation. In fact,
the circulating level and aortic accumulation of deamidated
lipocalin-2 is increased in mice treated with MMP9i. These
results suggest that by modulating the polyamine modiﬁcation
of, and protein interactions with, lipocalin-2, LA enhances the
stability of this adipokine in the circulation and facilitates its
accumulation in the arterial wall.
Polyamines are required for normal cellular function
through interactions with cellular macromolecules.23 They
are localized within secretory granules of protein- and
peptide-secreting cells (such as neutrophils) and are critically
involved in the correct biogenesis, homeostasis, and intracel-
lular trafﬁcking of these vesicles.45,46 Lipocalin-2 is produced
from neutrophils, which contain a variety of granules that are
exocytosed at different times to meet the demands, such as
adhesion to endothelium (secretory vesicles), migration
through basement membranes (gelatinase granules), and
phagocytosis, killing, and digestion of microorganisms (spe-
ciﬁc granules and azurophil granules).47 Polyamination of this
molecule may determine its selective packaging in speciﬁc
granules and the timing of release during exocytosis of
neutrophils. Spermidine and spermine also show high-afﬁnity
binding to phospholipids and nucleic acids. Thus, in addition
to protein interaction and stability, polyamines may also
modulate other biological functions of lipocalin-2, such as its
cellular uptake,48,49 and its phospholipid remodeling activity.8
As a carrier, lipocalin-2 may affect polyamine homeostasis
within the vasculature. Polyamination of molecules in endo-
thelial cells, such as RhoA, plays an important role in
endothelial integrity and function.50 Because polyamines
and NO are originated from the common precursor, arginine,
changes of polyamine metabolites may inﬂuence the eNOS-
NO metabolic pathway. In fact, accumulation of deamidated
lipocalin-2 induces eNOS uncoupling, leading to endothelial
dysfunction and vascular inﬂammation. On the other hand,
administration of the same amount of WT hlipocalin-2 alone
does not affect vascular reactivity, largely because of the lack
of deamidation triggers, including NEFAs and obesity.
Deamidated lipocalin-2 accumulates in aortae of HFD-fed
WT mice, which exhibit deteriorated vasodilator responses,
endothelial dysfunction, and elevated blood pressure.7 Lipoc-
alin-2 is a major gene target for mineralocorticoid receptor,
agonists of which are known mediators of vascular insulin
resistance and hypertension associated with obesity.51 In
humans, a causal relationship between lipocalin-2 and
development of hypertension has been suggested by the
association between single-nucleotide polymorphisms in the
gene encoding lipocalin-2 (LCN2).9 Plasma concentration of
lipocalin-2 is positively correlated with indices of obesity,
insulin resistance, and elevated blood pressure.5 Lifestyle
factors are well known to contribute to obesity-related
hypertension. The present study demonstrates that deami-
dated lipocalin-2 accumulates in arteries and causes vascular
derangement, ultimately facilitating the occurrence of arterial
hypertension. The ﬁndings highlight an important lipid-adipo-
kine interaction mechanism of excess LA intake-mediated
lipocalin-2 activation, a pathway that links overnutrition and
obesity to hypertensive conditions in human patients.
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Supporting Information 
  
   
 
 
 
 
 
 
 
 
Supplementary Figure 1. The gene expression of lipocalin-2 (Lcn2) and its receptors (NGALR and 
24p3R) was measured by QPCR using mRNA extracted from WT and Lcn2-KO mice fed with 8-
weeks of high fat diet (upper left panel). Serum adiponectin levels were quantified by ELISA 
(upper right panel) as described21. The aortic expression of various inflammatory gene markers in 
aortae was also evaluated and compared between WT and Lcn2-KO mice given 8-weeks of high 
fat diet (lower panel). Fold changes were calculated against the values of WT mice under standard 
chow. *, P < 0.05 vs WT group; n=3.   
  
 
 
 
 
 
 
 
Supplementary Figure 2. Mass spectrometric analysis revealed that both the NH2-terminal peptide 
with a mass of 1790.88 Da (left panel) and the COOH-terminal peptide with a mass of 2320.16 Da 
(right panel) were present in the mass spectra of HMW and LMW hlipocalin-2.  
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Supplementary Figure 3. In-gel digestion was performed for the HMW and LMW species of 
mlipocalin-2 (left panel). Mass spectrometric analysis revealed that a cluster of peptide peaks, with 
mass differences of 57 Da, 87 Da, 144 Da and 201 Da (right panel), were present in the mass 
spectrum of HMW, but not LMW mlipocalin-2, suggesting that this protein was polyaminated. 
  
HMW 
LMW 
HMW 
LMW
m/z 
m/z 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4. Immunoprecipitation was performed in pooled serum samples collected 
from lean [body mass index (BMI) ≤ 24] and obese (BMI ≥ 30) human subjects. The immune 
complex was separated by SDS-PAGE and Western blotting performed for detection of the 
precipitated lipocalin-2 (bottom panel), the polyamine modification (middle panel), and the bound 
MMP9 (upper panel) using specific antibodies.   
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Supplementary Figure 5. Aortae were collected from mice treated with vehicle, linoleic acid, 
hlipocalin-2, C87A or hlipocali-2 plus linoleic acid. Aortic rings were precontracted with 
phenylephrine (PE) and then exposed to sodium nitroprusside (SNP) in a cumulatively manner. 
The concentration response curves are presented as a percentage of the pre-contraction to PE. n=8-
10. 
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Supplementary Figure 6. WT mice (20-weeks old, under high fat diet) were treated with vehicle 
or difluoromethylornithine (DMFO, 1 mg/mouse, intraperitoneal injection). Serum was collected 
at different time points after treatment and subjected to Western blotting using antibody 
recognizing mlipocalin-2 (left panel). At 20 hours after treatment, perivascular adipose tissues 
around aortae were collected for Western blotting to detect lipocalin-2 content (right panel). 
